Competition for capital in the life sciences and pharmaceutical industry is fierce. Access to Canadian and US venture capital funding is an ongoing issue for many of our country's most innovative players. Uncertain capital markets coupled with rising drug development costs are leading to a lot of anxiety in the industry. Canadian biotechnology companies in particular are finding it a bumpy road to complete almost any round of financing and an initial public offering (IPO) is a rare event.
Without adequate capital, Canadian entrepreneurs cannot transform their scientific innovation into commercial opportunities. When participants in PwC's Canadian Life Sciences Industry Forecast 2007 were asked what the number-one barrier to successful commercialization was, 78% said access to capital. Almost half of the survey's participants said they are currently trying to raise capital and another 32% expect to raise capital by 2009.
50% of survey participants
32% of survey participants
Our corporate finance practice provides a full range of services to assist you with the raising of capital through IPOs and access to venture capital, private equity and other forms of funding including monetization of existing assets. Our tax planning services can help you take advantage of tax incentives and credits to ensure that more of your hard-earned capital is going where it should — to the development and commercialization of your intellectual property. Our licensing management practice can help you verify whether your royalty income from strategic partners is accurate and complete. In addition, we periodically host and sponsor events designed to connect Canadian companies to venture capital and private equity services.